Correction to: British Journal of Cancer (2011) 104, 781–789. doi:10.1038/bjc.2011.10
Since publication of this paper in February 2011, the authors have been made aware of an error in the name of the plant species used in their study. The plant name should be corrected to: Hemsleya amabilis Diels (incorrect spelling in paper: Hemsleya amalils Diels).
Change history
28 March 2012
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Additional information
The online version of the original article can be found at 10.1038/bjc.2011.10
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Boykin, C., Zhang, G., Chen, YH. et al. Erratum: Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation. Br J Cancer 106, 1248 (2012). https://doi.org/10.1038/bjc.2012.77
Published:
Issue Date:
DOI: https://doi.org/10.1038/bjc.2012.77
This article is cited by
-
Effects of erythropoietin on osteoblast proliferation and function
Clinical and Experimental Medicine (2014)
